| obesity and overweight | All results are NS for efficacy inferior to placebo in terms of cardiovascular events in SCOUT, 2010 | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| McMahon, 2000 | vs placebo | | | | | McMahon, 2002 | vs placebo | | | | | Smith, 2001 | vs placebo | | | | | SCOUT, 2010 | vs placebo | | cardiovascular events 1.16 [1.03; 1.31] | |
| Trial | Treatments | Patients | Method |
|---|
| McMahon, 2000 | (n=142) vs. (n=157) | | Sample size: 142/157 Primary endpoint: FU duration: | | McMahon, 2002 | (n=145) vs. (n=72) | | Sample size: 145/72 Primary endpoint: FU duration: | | Smith, 2001 | (n=142) vs. (n=69) | | Sample size: 142/69 Primary endpoint: FU duration: | | SCOUT, 2010 | sibutramine (n=4906) vs. placebo (n=4898) | overweight or obese patients with diabetes or a history of coronary or peripheral vascular disease or stroke, along with other CV risk factors | double blind Parallel groups Sample size: 4906/4898 Primary endpoint: death, MI, stroke FU duration: 3.4 year |
|
